SLC5A2 and diabetes mellitus: Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a novel class of oral diabetes drugs that block glucose reabsorption via SGLT2 in the proximal tubules of the kidneys, leading to increased glucose excretion in the urine.